Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer

Int J Clin Pharmacol Ther. 2004 Nov;42(11):650-1. doi: 10.5414/cpp42650.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents
  • Antibiotics, Antineoplastic / adverse effects
  • Antibiotics, Antineoplastic / pharmacokinetics
  • Antibiotics, Antineoplastic / therapeutic use*
  • Area Under Curve
  • Benzenesulfonates / adverse effects
  • Benzenesulfonates / therapeutic use*
  • Cholangiocarcinoma / drug therapy*
  • Doxorubicin / adverse effects
  • Doxorubicin / pharmacokinetics
  • Doxorubicin / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Liver Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / adverse effects
  • Pyridines / therapeutic use*
  • Sorafenib

Substances

  • Anti-Bacterial Agents
  • Antibiotics, Antineoplastic
  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Doxorubicin
  • Sorafenib